CSE:AIAI - Post Discussion
Post by
partystocker on Mar 12, 2022 12:03pm
$MEND.c Receives High Recognition For Its AI-Based Platform
Nusosene (CSE: MEND) has received further recognition validating its AI-based platform.
$MEND.c CSO recently received the “Highly Cited Paper” award from the peer-reviewed journal Exploration of Medicine for his research supporting $MEND.c’s platform's ability to accurately stratify patient subpopulations, even within relatively small study samples.
This research strongly validates Nurosene's AI platform and provides novel insights into Alzheimer's disease, which has a diagnostics and therapeutics market valued at US$7 billion.
$MEND.c is currently on a bounce from all-time lows, approaching a retest of the 50MA. Shares are currently trading at $.6 and the company is valued at $24.17 million.
https://ceo.ca/@newswire/nurosenes-cso-and-director-of-bioinformatics-receives
Be the first to comment on this post